Company Name
Skye Bioscience, Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US83086J2006
CIK:
0001516551
CUSIP:
83086J101
Currency:
USD
Full Time Employees:
16
Phone:
858 410 0266
Website:
https://skyebioscience.com
Fiscal Year End:
December
IPO Date:
Apr 02, 2015
Description:
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Address:
11250 El Camino Real, San Diego, CA, United States, 92130